The evaluation of breast tissue using nuclear imaging is dependent upon the delivery and uptake of the isotope by breast tissue. This is dependent upon blood flow to the breast and functioning mitochondria. This 2-part study investigated (1) differences in uptake of sestamibi when blood flow is enhanced (breast enhanced scintigraphy test [BEST]), and (2) differences in isotope uptake in normal (Nl) breast tissue, inflammatory changes in breast tissue (ICB), and breast cancer (CA). In the first part of the study, 10 women were compared using both Miraluma and BEST imaging; in the second part, 195 people were studied using BEST imaging only. The results were compared with histopathologic specimens. Little difference was noted between Miraluma and BEST imaging in the first part. Women with ICB showed a statistically significant (P< .05) increase in isotope uptake using BEST imaging. This difference was even more significant (P< .005) in women with CA. During the second part of the study, BEST imaging demonstrated an exponential increase in tracer uptake. When maximal count activity was compared, there was a statistically significant (P<.001) difference between Nl and ICB, between ICB and atypia (A), and between A and CA. BEST imaging demonstrated significant increases in isotope delivery when compared with Miraluma imaging. These differences allowed differentiation of breast tissue, including the detection of early changes in breast tissue.
References
1.
Khalkhali I, Cutrone JA, Mena IG, et al.Scintimammography: the complementary role of Tc-99m sestamibi prone breast imaging for the diagnosis of breast carcinoma. Radiology. 1995;196:421-426.
2.
Khalkhali I, Villanueva-Meyer J, Edell SL, et al.Diagnostic accuracy of 99mTc-sestamibi breast imaging: multicenter trial results. J Nucl Med. 2000;41:1973-1979.
3.
Carvalho PA, Chiu ML, Kronauge JF, et al.Subcellular distribution and analysis of technetium-99m-MIBI in isolated perfused rat hearts. J Nucl Med. 1992;33:1516-1522.
4.
Piwnica-Worms D, Kronauge JF, Chiu ML.Uptake and retention of hexakis (2-methoxyisobutyl isonitrile) technetium (I) in cultured chick myocardial cells: mitochondrial and plasma membrane potential dependence. Circulation. 1990;82:1826-1838.
5.
Vanoli C, Antronaco R, Giovanella L, Ceriani L, Sessa F, Fugazzola C.99mTc-MIBI characterization of breast micro-calcifications: correlations with scintigraphic and histopathologic findings. Radiol Med. 1999;98:19-25.
6.
Benard F, Lefebvre B, Beuvon F, Langlois MF, Bisson G.Rapid washout of technetium-99m-MIBI from a large parathyroid adenoma. J Nucl Med. 1995;36:241-243.
7.
Arbab AS, Koizumi K, Hemmi A, et al.Tc-99m-MIBI scintigraphy for detecting parathyroid adenoma and hyperplasia. Ann Nucl Med. 1997;11:45-49.
8.
Chiu ML, Kronauge JF, Piwnica-Worms D.Effect of mitochondrial and plasma membrane potentials on accumulation of hexakis (2-methoxyisobutylisonitrile) technetium (I) in cultured mouse fibroblasts. J Nucl Med. 1990;31:1646-1653.
9.
Backus M, Piwnica-Worms D, Hockett D, et al.Microprobe analysis of Tc-MIBI in heart cells: calculation of mitochondrial membrane potential. Am J Physiol. 1993;265:C178-C187.
10.
Scopinaro F, De Vincentis G, Pani R, et al.99Tcm-MIBI uptake in green plants. Nucl Med Commun. 1994;15:905-915.
11.
Arbab AS, Koizumi K, Toyama K, Araki T.Uptake of technetium-99m-tetrofosmin, technetium-99m-MIBI and thallium- 201 in tumor cell lines. J Nucl Med. 1996;37:1551-1556.
12.
Crane P, Laliberte R, Heminway S, Thoolen M, Orlandi C.Effect of mitochondrial viability and metabolism on technetium-99m-sestamibi myocardial retention. Eur J Nucl Med. 1993;20:20-25.
13.
Piwnica-Worms DP, Kronauge JF, LeFurgey A, et al.Mitochondrial localization and characterization of 99Tc-SESTAMIBI in heart cells by electron probe X-ray microanalysis and 99Tc-NMR spectroscopy. Magn Reson Imaging. 1994;12:641-652.
14.
Pach J, Hubalewska-Hola A, Szybinski Z, Pach D.New possibilities in scintigraphy detection of carbon monoxide cardiotoxicity. Przegl Lek. 2001;58:182-184.
15.
Piwnica-Worms D, Chiu ML, Kronauge JF.Detection of adriamycin-induced cardiotoxicity in cultured heart cells with technetium 99m-SESTAMIBI. Cancer Chemother Pharmacol. 1993;32:385-391.
16.
Gunningham SP, Currie MJ, Han C, et al.VEGF-B expression in human primary breast cancers is associated with lymph node metastasis but not angiogenesis. J Pathol. 2001;193:325-332.
17.
Pepper MS.Extracellular proteolysis and angiogenesis. Thromb Haemost. 2001;86:346-355.
18.
Zhong S, Zhang Z, Li S.Significance of vascular endothelial growth factor expression in colorectal cancer. Zhonghua Nei Ke Za Zhi. 2001;40:514-516.
19.
Fleming RM.Atherosclerosis: understanding the relationship between coronary artery disease and stenosis flow reserve. In: Chang JC, ed. Textbook of Angiology. New York, NY: Springer-Verlag; 1999:381-387.
20.
Fleming RM.Nuclear cardiology: its role in the detection and management of coronary artery disease. In: Chang JC, ed. Textbook of Angiology. New York, NY: Springer-Verlag; 1999:397-406.
21.
Fleming RM, Boyd L, Forster M.Angina is caused by regional blood flow differences—proof of a physiologic (not anatomic) narrowing. Paper presented at: Joint Session of the European Society-American College of Cardiology, ACC 49th Annual Scientific Sessions; March 12, 2000; Anaheim, CA.
22.
Fleming RM.Regional blood flow differences induced by high dose dipyridamole explain etiology of angina. Paper presented at:3rd International College of Coronary Artery Disease From Prevention to Intervention; October 4, 2000; Lyon, France.
23.
Fleming RM, Boyd LB, Kubovy C.Myocardial perfusion imaging using high dose dipyridamole defines angina: the difference between coronary artery disease (CAD) and coronary lumen disease (CLD). Paper presented at:48th Annual Scientific Session of the Society of Nuclear Medicine; June 27, 2001; Toronto, Ontario, Canada.
24.
Fleming RM.Coronary artery disease is more than just coronary lumen disease. Am J Cardiol. 2001;88:599-600.
25.
Fleming RM, Rose CH, Feldmann KM.Comparing a high-dose dipyridamole SPECT imaging protocol with dobutamine and exercise stress testing protocols. Angiology. 1995;46:547-556.
26.
Holdright DR, Lindsay DC, Clarke D, Fox K, Poole-Wilson PA, Collins P.Coronary flow reserve in patients with chest pain and normal coronary arteries. Br Heart J. 1993;70:513-519.
27.
Fleming RM, Dooley WC, Boyd LB, Kubovy C.Breast enhanced scintigraphy testing (BEST)—increased accuracy in detecting breast cancer accomplished by combining breast and cardiac imaging. Paper presented at:48th Annual Scientific Session of the Society of Nuclear Medicine; June 26, 2001; Toronto, Ontario, Canada.
28.
Folkman J, Merler E, Abernathy C, Williams G.Isolation of a tumor factor responsible for angiogenesis. J Exp Med. 1971; 133:275-288.
29.
Stewart RJ, Panigraphy D, Flynn E, Folkman J.Vascular endothelial growth factor expression and tumor angiogenesis are regulated by androgens in hormone responsive human prostate carcinoma: evidence for androgen dependent destabilization of vascular endothelial growth factor transcripts. J Urol. 2001;165:688-693.
30.
Fleming RM.The pathogenesis of vascular disease. In: Chang JC, ed. Textbook of Angiology. New York, NY: Springer-Verlag; 1999:787-798.
